TrialBlood advances2025

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.

Jason Westin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.